SUPRIYA share price, P/E, ROE & financials

On 6 Nov 2026, Supriya Lifescience was priced at ₹695.80, or 28.2× trailing earnings, against an industry P/E of 49.1×, and the shares are 36% below their 52-week high. Sales and net profit grew 21% and 33% a year over 3 years, with ROCE of 22% and ROE of 19%. It carries very little debt, and its dividend yield is 0.1%. It is a small-cap company with a market cap of ₹5,600 Cr, ranked 6th of 20 Biotechnology companies by market cap; the shares rose 9.2% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹866.90
Day high: ₹869.50
Day low: ₹695.70
Prev. close: ₹869.60
Volume: 19.7 L

Health check

4 good · 1 fair · 1 to check

ReturnsAhead
+9.2% over a year, better than 6 of 7 peers.
Price tagCheaper
P/E 28.2 vs industry 49.1.
GrowthStrong
Sales +21.2%, profit +32.5% a year over 3 years.
ProfitabilityStrong
ROCE 22.3% vs peer median 2.8%.
Balance sheetFair
Practically debt-free, Piotroski 4 of 9.
Red flags2 to check
Quarterly profit down 30.9% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Biotechnology

19 listed peers. Screen the industry

Small cap

₹5,600 Cr, #6 of 20 in its industry by size.

Defensive

Beta 0.67 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹873 Cr · profit ₹198 Cr

Market cap: ₹5,600 Cr; Small cap
P/E: 28.2; Industry 49.1
Price to book: 4.68; Peers 4.52
Dividend yield: 0.14%
ROE: 19.1%; Peers 1.6%
ROCE: 22.3%; Peers 2.8%
Debt to equity: 0.00; Debt ₹5.44 Cr
EPS (TTM): ₹24.65; Face value ₹2
OPM (TTM): 33.2%; Net margin 22.7%
Sales growth: +30.8%; Latest quarter vs a year ago
Profit growth: −30.9%; Latest quarter vs a year ago
Price to sales: 6.42; EV/EBITDA 19.1

Strengths

Return on equity of 19.1%.
Return on capital employed of 22.3%.
Practically debt-free.
Quarterly sales up 30.8% on a year ago.
Net margin of 22.7%.

Risks to check

Quarterly profit down 30.9% on a year ago.
36% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Supriya Lifescience

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals in India and internationally. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antihypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides finished formulation products. In addition, the company…

Headquarters: Mumbai
Employees: 607
Sector: Healthcare
ISIN: INE07RO01027
Website: supriyalifescience.com

Price range

52 weeks

₹545.50₹1,085.00

Today

₹695.70₹869.50

Avg volume (3M): 3.2 L
1-year return: plus 9.2%
From 52-week high: minus 35.9%

Peers · Biotechnology

Compare with peers Screen the whole industry

Company
BIOCONBiocon	365.10	plus 0.86%	59,794	122.5	1.73	2.8%	1.0%	19.4%	15.3%	−5.9%	0.14%	minus 4.9%
ANTHEMAnthem Biosciences	915.55	plus 0.22%	51,594	84.6	15.74	26.8%	20.4%	41.4%	26.2%	15.4%	0.22%	plus 30.1%
ONESOURCEOnesource Specialty Pharma	1,599.80	plus 1.13%	18,346	–	3.10	0.3%	0.0%	23.5%	232.3%	–	0.00%	minus 13.7%
CONCORDBIOConcord Biotech	632.60	minus 5.96%	13,236	47.4	6.48	16.7%	14.3%	34.5%	8.0%	2.8%	0.60%	minus 7.5%
BLUEJETBlue Jet Healthcare	553.80	minus 3.91%	9,607	34.5	4.52	24.0%	19.9%	31.4%	9.4%	15.7%	0.22%	minus 5.0%
SUPRIYASupriya Lifescience	695.80	minus 19.99%	5,600	28.2	4.68	22.3%	19.1%	21.4%	21.2%	32.5%	0.14%	plus 9.2%
ZOTAZota Health Care	1,231.10	plus 1.01%	4,264	–	6.82	−7.3%	−24.1%	0.1%	56.7%	–	0.08%	minus 21.9%
DCALDishman Carbogen Amcis	156.64	minus 0.56%	2,456	152.1	0.37	2.7%	1.6%	16.1%	7.5%	–	0.00%	minus 47.1%
Median of 7 peers	–	0.22%	13,236	84.6	4.52	2.8%	1.6%	23.5%	15.3%	9.1%	0.14%	−7.5%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
145	200	206	277	190
93.4	127	134	179	142
51.7	72.6	72.1	97.6	47.5
35.6%	36.4%	34.9%	35.3%	25.0%
2.7	2.7	2.6	3.5	2.6
0.5	0.4	0.5	0.5	0.4
6.5	6.6	6.8	8.5	8.9
–	–	−0.5	–	–
47.4	68.3	66.9	92.1	40.8
26.6%	26.2%	25.8%	19.4%	41.1%
34.8	50.4	49.7	74.2	24
4.32	6.27	6.17	9.22	2.99

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +21.2%
Profit CAGR 3Y: +32.5%
EPS CAGR 3Y: +32.5%
ROE: 19.1%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
451	557	680	802
–	+23.6%	+21.9%	+18.1%
324	384	423	519
127	174	256	283
28.2%	31.1%	37.7%	35.3%
12.6	12	9.9	19.2
1.7	3.7	0.5	1.4
11.8	15.8	20.4	28.4
−2.8	−0.3	3.2	2.4
123	166	248	275
27.2%	28.1%	24.4%	23.9%
89.9	119	188	209
–	+32.6%	+57.8%	+11.3%
11.16	14.80	23.35	25.98

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
16.1	16.1	16.1	16.1
683	799	981	1,182
22.5	5.5	5.4	5.4
98.4	101	115	154
820	921	1,117	1,357
328	457	609	723
67.6	149	158	35.5
25.1	61.1	57	90
154	75	79.1	78.8
245	179	214	429
820	921	1,117	1,357

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
63.6	113	165	186
−124	−174	−152	−176
−10.3	−22.4	−8.2	−9.9
−70.3	−82.6	4.2	−0.3
−108	−146	−162	−152
−44.3	−32.3	2.3	33.5
−4.8	−4.8	−6.4	−8

Shareholding pattern

Source: NSE filings

68.3%

promoters

Promoters68.30%
Public31.70%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	68.30%	31.70%	0.00
30 Jun 2026	68.30%	31.70%	0.00
31 Mar 2026	68.30%	31.70%	0.00
31 Dec 2025	68.30%	31.70%	0.00
30 Sep 2025	68.30%	31.70%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you